| 17.07 -1.52 (-8.18%) | 01-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 21.68 |
1-year : | 23.11 |
| Resists | First : | 18.56 |
Second : | 19.79 |
| Pivot price | 17.97 |
|||
| Supports | First : | 16.58 |
Second : | 13.8 |
| MAs | MA(5) : | 18.36 |
MA(20) : | 17.79 |
| MA(100) : | 16.17  |
MA(250) : | 11.17 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 48.1 |
D(3) : | 65.6 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 20.32 | Low : | 5.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TVTX ] has closed above bottom band by 20.9%. Bollinger Bands are 6.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.78 - 18.88 | 18.88 - 18.97 |
| Low: | 16.55 - 16.66 | 16.66 - 16.76 |
| Close: | 16.87 - 17.04 | 17.04 - 17.21 |
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Tue, 14 Jan 2025
Travere Therapeutics (NASDAQ:TVTX) Shares Down 4.2% - Should You Sell? - MarketBeat
Mon, 06 Jan 2025
Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 2,066 Shares of Stock - MarketBeat
Mon, 06 Jan 2025
Travere Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Thu, 26 Dec 2024
Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain - Yahoo Finance
Thu, 19 Dec 2024
Travere Therapeutics: Cautiously Bullish Based On Improving Revenue (NASDAQ:TVTX) - Seeking Alpha
Thu, 14 Nov 2024
Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 87 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 99.1 (%) |
| Shares Short | 7,410 (K) |
| Shares Short P.Month | 6,970 (K) |
| EPS | -4.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.39 |
| Profit Margin | -172.8 % |
| Operating Margin | -89.1 % |
| Return on Assets (ttm) | -26.2 % |
| Return on Equity (ttm) | -280 % |
| Qtrly Rev. Growth | 69.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.33 |
| EBITDA (p.s.) | -2.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -272 (M) |
| Levered Free Cash Flow | -215 (M) |
| PE Ratio | -3.78 |
| PEG Ratio | 0 |
| Price to Book value | -43.77 |
| Price to Sales | 7.3 |
| Price to Cash Flow | -5.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|